<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828460</url>
  </required_header>
  <id_info>
    <org_study_id>8133</org_study_id>
    <nct_id>NCT04828460</nct_id>
  </id_info>
  <brief_title>Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients</brief_title>
  <acronym>COVATRANS</acronym>
  <official_title>Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19&#xD;
      pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show&#xD;
      very good vaccine protection in the general population and good short-term tolerance. The&#xD;
      efficacy of these vaccines ranges from 62 to 95%, which is particularly remarkable,&#xD;
      especially for mRNA vaccines. Nevertheless, these studies do not report the vaccine response&#xD;
      in organ transplant patients.&#xD;
&#xD;
      It is known that transplant patients have lower vaccine responses than immunocompetent&#xD;
      patients due to some degree of immunosuppression.&#xD;
&#xD;
      Therefore, the investigators are interested in evaluating the vaccine response of organ&#xD;
      transplant recipients after vaccination against SARS- CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies</measure>
    <time_frame>One month after the 2nd injection of the COVID-19 vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the seroconversion between different vaccines</measure>
    <time_frame>At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies</measure>
    <time_frame>At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the patients characteristics associated with seroconversion</measure>
    <time_frame>At Month 24 after the 2nd injection of the COVID-19 vaccine</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Covid19</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Kidney transplant recipients who receive Covid-19 vaccine</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant recipients followed in French transplant centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient, male or female, adult or child (15 years and older)&#xD;
&#xD;
          -  Patient vaccinated against SARS-CoV-2 as part of routine care, and having received the&#xD;
             2 injections&#xD;
&#xD;
          -  Solid organ transplant recipient&#xD;
&#xD;
          -  Transplantation for more than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anaphylactic shock or known allergy to PEG&#xD;
&#xD;
          -  Known history of COVID or positive Covid serology in the 3 months preceding inclusion&#xD;
&#xD;
          -  Formal contraindication to an intra-muscular injection&#xD;
&#xD;
          -  Impossibility to give the subject informed information (subject in emergency&#xD;
             situation, difficulties in understanding the subject, ...)&#xD;
&#xD;
          -  Subject under legal protection&#xD;
&#xD;
          -  Subject under guardianship or curatorship&#xD;
&#xD;
          -  Patient having expressed his opposition to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Ohlmann, MD</last_name>
    <phone>0369551320</phone>
    <phone_ext>33</phone_ext>
    <email>sophie.ohlmann@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Ohlmann, MD</last_name>
      <phone>0369551320</phone>
      <phone_ext>33</phone_ext>
      <email>sophie.ohlmann@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>seroconversion</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>vaccination</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

